© The Author 2017. Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

doi:10.1093/ecco-jcc/jjx052 Advance Access publication April 27, 2017 OXFORD

Corrigendum

Journal of Crohn's and Colitis, 2017, 1510

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

David T. Rubin,^a Russell D. Cohen,^a William J. Sandborn,^b Gary R. Lichtenstein,^c Jeffrey Axler,^d Robert H. Riddell,^e Cindy Zhu,^f Andrew C. Barrett,^f Enoch Bortey,^f William P. Forbes^f

^aInflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA ^bDivision of Gastroenterology, University of California [UC] San Diego and UC San Diego Health System, San Diego, CA, USA ^cDivision of Gastroenterology, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA ^dToronto Digestive Disease Associates, Toronto, ON, Canada ^eDepartment of Pathology and Laboratory Medicine, Mt Sinai Hospital, Toronto, ON, Canada ^fSalix Pharmaceuticals, Raleigh, NC, USA

doi:10.1093/ecco-jcc/jjx032

This article has been updated to correct an error to the n value for patients randomised to treatment in Figure 1.

